The company partners with healthcare professionals to provide therapeutic solutions for acute medical conditions, such as Acute Coronary Syndromes and Atrial Fibrillation, and measures success by the number of Major Adverse Cardiac Events prevented with its product Aggrastat®. Correvio also offers a Medical Information Centre available 24/7/365 to provide medical information support. The company's revenue is generated from the sale of its commercialized products, which include Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. Correvio operates in Europe and the Rest of the World geographic segments.